Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: Results from the SENTRY antimicrobial surveillance program (2006-09)

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 2070-2074

  Gales, Ana C ^a   Jones, Ronald N ^b   Sader, Hélio S ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b JMI LABORATORIES   (United States)

Author keywords

Antimicrobial activity; Carbapenems; Drug resistance; Polymyxins

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOGEOGRAPHIC REGION; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BRAZIL; COLISTIN; DRUG RESISTANCE, BACTERIAL; EUROPE; GEOGRAPHY; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; POPULATION SURVEILLANCE;

EID: 80051701366     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr239     Document Type: Article

References (11)

1. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
2. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006; 12: 315-21.
3. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11.
4. Yau W, Owen RJ, Poudyal A et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 2009; 58: 138-44.
5. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrugresistant infection. J Antimicrob Chemother 2010; 65: 1119-25.
6. Higgins PG, Dammhayn C, Hackel M et al. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 233-8.
7. Miriagou V, Cornaglia G, Edelstein M et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 2010; 16: 112-22.
8. Suh JY, Son JS, Chung DR et al. Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. Antimicrob Agents Chemother 2010; 54: 560-2.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement (June 2010 Update) M100-S20U. CLSI, Wayne, PA, USA, 2010.
10. EUCAST. Breakpoint Tables For Interpretation of MICs and Zone Diameters. Version 1.1, April 2010. http://www.eucast.org/clinical_breakpoints/ (10 June 2010, date last accessed).
11. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 2003; 24: 121-34.